Efficacy and safety of intravitreal aflibercept (Eylea®) therapy using a proactive treat-and-extend regimen in neovascular AMD

Article

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Download Supplement

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Related Content
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

Joong Hun Kim, MD
August 5th 2025
Article

In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction

Site Logo

Updates From Angiogenesis-2022

August 5th 2025
Podcast
Site Logo

Early Experience of Aflibercept 8mg (EYLE® 8mg) in Routine Clinical Practice

August 5th 2025
Article
Site Logo

Updates from ASRS 2021

August 5th 2025
Podcast
Site Logo

Three-year outcomes of aflibercept 8mg in neovascular age related macular degeneration and diabetic macular edema

Sponsored by Bayer
August 5th 2025
Article
Site Logo

A Turning Point in Retinal Neovascular Diseases

Sponsored by Bayer
August 5th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.